Back to top

Has Intuitive Surgical (ISRG) Outpaced Other Medical Stocks This Year?

Read MoreHide Full Article

Investors focused on the Medical space have likely heard of Intuitive Surgical (ISRG - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Intuitive Surgical is one of 758 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ISRG is currently sporting a Zacks Rank of #2 (Buy).

Within the past quarter, the Zacks Consensus Estimate for ISRG's full-year earnings has moved 5.35% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the most recent data, ISRG has returned 43.23% so far this year. Meanwhile, the Medical sector has returned an average of 4.74% on a year-to-date basis. This shows that Intuitive Surgical is outperforming its peers so far this year.

Breaking things down more, ISRG is a member of the Medical - Instruments industry, which includes 88 individual companies and currently sits at #120 in the Zacks Industry Rank. Stocks in this group have lost about 9.29% so far this year, so ISRG is performing better this group in terms of year-to-date returns.

Investors in the Medical sector will want to keep a close eye on ISRG as it attempts to continue its solid performance.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Intuitive Surgical, Inc. (ISRG) - free report >>

More from Zacks Tale of the Tape

You May Like